Dyax Receives “Complete Response” For HAE Drug; REMS Will Be Required

Dyax is joining a growing group of companies that have seen their approvals delayed, via a "complete response" letter, to work out a Risk Evaluation and Mitigation Strategy. The Cambridge, Mass. biotech got such a letter March 26 for ecallantide, its drug to treat acute attacks of hereditary angioedema

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet